Cargando…
A recombinant chimera comprising the R1 and R2 repeat regions of M. hyopneumoniae P97 and the N-terminal region of A. pleuropneumoniae ApxIII elicits immune responses
BACKGROUND: Infection by Mycoplasma hyopneumoniae and Actinobacillus pleuropneumoniae, either alone or together, causes serious respiratory diseases in pigs. RESULTS: To develop an efficient multi-disease subunit vaccine against these pathogens, we produced a chimeric protein called Ap97, which comp...
Autores principales: | Lee, Seung Heon, Lee, Seungwoo, Chae, Chanhee, Ryu, Doug-Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932138/ https://www.ncbi.nlm.nih.gov/pubmed/24533486 http://dx.doi.org/10.1186/1746-6148-10-43 |
Ejemplares similares
-
Development of Actinobacillus pleuropneumoniae ApxI, ApxII, and ApxIII-specific ELISA methods for evaluation of vaccine efficiency
por: Jung, Myunghwan, et al.
Publicado: (2019) -
Porcine CD18 mediates Actinobacillus pleuropneumoniae ApxIII species-specific toxicity
por: Vanden Bergh, Philippe G.A.C., et al.
Publicado: (2009) -
A Recombinant Chimera Vaccine Composed of LTB and Mycoplasma hyopneumoniae Antigens P97R1, mhp390 and P46 Elicits Cellular Immunologic Response in Mice
por: Liu, Wei, et al.
Publicado: (2023) -
Immunological study of an attenuated Salmonella Typhimurium
expressing ApxIA, ApxIIA, ApxIIIA and OmpA of Actinobacillus
pleuropneumoniae in a mouse model
por: HUR, Jin, et al.
Publicado: (2015) -
Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice
por: Shin, Sung Jae, et al.
Publicado: (2007)